Therapeutic antibodies for infectious diseases

Bulletin of the World Health Organization

Volumn 95, Issue 3, 2017, Pages 235-237

  Sparrow, Erin ^a   Friede, Martin ^b   Sheikh, Mohamud ^a   Torvaldsen, Siranda ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX ANTIBODY; BOTULISM ANTIBODY; CYTOMEGALOVIRUS ANTIBODY; DIPHTHERIA ANTIBODY; HEPATITIS A ANTIBODY; HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; HERPES ZOSTER IMMUNOGLOBULIN; MEASLES ANTIBODY; MONOCLONAL ANTIBODY; OBILTOXAXIMAB; PALIVIZUMAB; POLYCLONAL ANTIBODY; RABIES IMMUNOGLOBULIN; RAXIBACUMAB; RECOMBINANT DNA; RUBELLA ANTIBODY; STAPHYLOCOCCUS AUREUS ANTIBODY; TETANUS ANTIBODY; UNCLASSIFIED DRUG; VACCINIA ANTIBODY; ANTIBODY; ANTIINFECTIVE AGENT;

ANTHRAX; AUTOIMMUNE DISEASE; BOTULISM; CLINICAL OUTCOME; CYTOMEGALOVIRUS INFECTION; DIPHTHERIA; HEPATITIS A; HEPATITIS B; HEPATITIS C; HERPES ZOSTER; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFECTION; MEASLES; NEOPLASM; NEWBORN MORTALITY; NEWBORN TETANUS; NONHUMAN; NOTE; PATIENT SAFETY; PREGNANT WOMAN; RABIES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; RUBELLA; SMALLPOX; STAPHYLOCOCCAL BACTEREMIA; TETANUS; VACCINATION; AFRICA; ANIMAL; COMMUNICABLE DISEASE; IMMUNOLOGY;

AFRICA, WESTERN; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBODIES; ANTIBODIES, MONOCLONAL; COMMUNICABLE DISEASES; HUMANS;

EID: 85014635920     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.16.178061     Document Type: Note

References (18)

1. Blencowe H, Lawn J, Vandelaer J, Roper M, Cousens S. Tetanus toxoid immunization to reduce mortality from neonatal tetanus. Int J Epidemiol. 2010 Apr;39 Suppl 1:i102-9 doi:http://dx.doi.org/10.1093/ije/dyq027 PMID: 20348112
2. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000 Oct;13(4):602-14 doi:http://dx.doi.org/10.1128/CMR.13.4.602-614.2000 PMID: 11023960
3. Ian Gust AO. Role of passive immunotherapies in managing infectious outbreaks. Biologicals. 2012 May;40(3):196-9 doi:http://dx.doi.org/10.1016/j.biologicals.2012.01.001 PMID: 22361391
4. Graham BS, Ambrosino DM. History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS. 2015 May;10(3):129-34 doi:http://dx.doi.org/10.1097/COH.0000000000000154 PMID: 25760933
5. Immune globulins [Internet]. Silver Spring: US Food and Drug Administration; 2016. Available from: http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm127589.htm [cited 2016 Oct 8].
6. Licensed biological products with supporting documents. Silver Spring: US Food and Drug Administration; 2016. Available from: http://www.fda.gov/BiologicsBloodVaccines/ucm133705.htm [cited 2016 Oct 8].
7. Medicines [Internet]. London: European Medicines Agency; 2016. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landing_page.jsp [cited 2016 Oct 8].
8. Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs. 2009 Sep-Oct;1(5):443-52 doi:http://dx.doi.org/10.4161/mabs.1.5.9448 PMID: 20065641
9. Goodman JL. Studying “secret serums”-toward safe, effective Ebola treatments. N Engl J Med. 2014 Sep 18;371(12):1086-9 doi:http://dx.doi.org/10.1056/NEJMp1409817 PMID: 25140857
10. McCarthy M. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ. 2014 Sep 04;349 sep04 10:g5488 doi:http://dx.doi.org/10.1136/bmj.g5488 PMID: 25189475
11. LeafBiol announces conclusion of ZMapp™ clinical trial. San Diego: Mapp Biopharmaceauticals-Leaf Biol; 2016. Available from http://mappbio.com/leafbio-announces-conclusion-of-zmapp-clinical-trial/ [cited 2016 Jul 27].
12. Hiatt A, Pauly M, Whaley K, Qiu X, Kobinger G, Zeitlin L. The emergence of antibody therapies for Ebola. Hum Antibodies. 2015 Dec 23;23(3-4):49-56 doi:http://dx.doi.org/10.3233/HAB-150284 PMID: 27472862
13. Hiatt A, Whaley KJ, Zeitlin L. Plant-derived monoclonal antibodies for prevention and treatment of infectious disease. Microbiol Spectr. 2014 Feb;2(1):AID-0004-2012 doi:http://dx.doi.org/10.1128/microbiolspec.AID-0004-2012 PMID: 26082108
14. Klinguer-Hamour C, Caussanel V, Beck A. Anticorps thérapeutiques et maladies infectieuses. Med Sci (Paris). 2009 Dec;25(12):1116-20 French. doi:http://dx.doi.org/10.1051/medsci/200925121116 PMID: 20035689
15. Oleksiewicz MB, Nagy G, Nagy E. Anti-bacterial monoclonal antibodies: back to the future? Arch Biochem Biophys. 2012 Oct 15;526(2):124-31 doi:http://dx.doi.org/10.1016/j.abb.2012.06.001 PMID: 22705202
16. Berry JD, Gaudet RG. Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology. N Biotechnol. 2011 Sep;28(5):489-501 doi:http://dx.doi.org/10.1016/j.nbt.2011.03.018 PMID: 21473942
17. International clinical trials registry platform (ICTRP). Geneva: World Health Organization: 2016. Available from: http://www.who.int/ictrp/en/ [cited 2016 Nov 11].
18. R&D Blueprint for action to prevent epidemics [Internet]. Geneva: World Health Organization; 2016. Available from: http://www.who.int/csr/research-and-development/blueprint/en/ [cited 2016 Nov 15].